Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD8 alpha antibody (Biotin)

CD8A Reactivity: Mouse FACS Host: Rat Monoclonal 53-6-7 Biotin
Catalog No. ABIN135121
  • Target See all CD8 alpha (CD8A) Antibodies
    CD8 alpha (CD8A) (CD8a Molecule (CD8A))
    Reactivity
    • 193
    • 118
    • 40
    • 37
    • 11
    • 7
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    Mouse
    Host
    • 144
    • 130
    • 99
    • 1
    Rat
    Clonality
    • 270
    • 100
    • 1
    Monoclonal
    Conjugate
    • 132
    • 43
    • 30
    • 25
    • 25
    • 8
    • 6
    • 6
    • 6
    • 6
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This CD8 alpha antibody is conjugated to Biotin
    Application
    • 287
    • 106
    • 93
    • 66
    • 54
    • 46
    • 42
    • 24
    • 15
    • 15
    • 14
    • 9
    • 8
    • 7
    • 6
    • 6
    • 6
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS)
    Specificity
    Mouse CD8α, Mr 32-34 kDa
    Characteristics
    Rat Anti-Mouse CD8a-BIOT
    Immunogen
    Spleen cells or thymocyte membranes
    Clone
    53-6-7
    Isotype
    IgG2a
    Top Product
    Discover our top product CD8A Primary Antibody
  • Application Notes
    • Applications: FC - Quality tested , IHC-FS - Reported in literature , ICC - Reported in literature , IP - Reported in literature , Depletion - Reported in literature , Block - Reported in literature
    • Working Dilutions: Flow Cytometry Purified (UNLB) antibody 2 g/106 cells FITC and BIOT conjugates 2 g/106 cells AF488 conjugate 1 g/106 cells PE, APC, SPRD, PE/TXRD, CY5, PE/CY5.5, PE/CY7, 0.2 g/106 cells APC/CY5.5, APC/CY7, PACBLU, AF647, and AF700 conjugates For flow cytometry, the suggested use of these reagents is in a final volume of 100 L
    Comment

    In vivo and in vitro depletion of CD8a+ cells

    Sample Volume
    1 mL
    Restrictions
    For Research Use only
  • Concentration
    0.5 mg/mL
    Buffer
    0.5 mg in 1.0 mL of PBS/Sodium azide
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handling Advice
    Protect conjugated products from light.
    Each reagent is stable for the period shown on the bottle label if stored as directed.
    Storage
    4 °C
    Storage Comment
    Store at 2-8°C
  • Target
    CD8 alpha (CD8A) (CD8a Molecule (CD8A))
    Alternative Name
    CD8a (CD8A Products)
    Synonyms
    cd8 antibody, LOC100136450 antibody, BB154331 antibody, Ly-2 antibody, Ly-35 antibody, Ly-B antibody, Lyt-2 antibody, zgc:136643 antibody, CD8 antibody, Leu2 antibody, MAL antibody, p32 antibody, RHACD8-4 antibody, CD8a molecule antibody, uncharacterized LOC100125537 antibody, CD8 alpha antibody, CD8 antigen, alpha chain antibody, T-cell surface glycoprotein CD8 alpha chain antibody, Cd8a antibody, LOC100125537 antibody, LOC100136450 antibody, CD8A antibody, cd8a antibody, LOC100126556 antibody
    Background
    In the mouse, CD8 exists in two forms: (i) a CD8 heterodimer composed of an chain (CD8/Lyt-2) and a chain (CD8/Lyt-3), and (ii) a homodimer of two chains. The heterodimer is found on the surface of essentially all thymocytes and the suppressor/cytotoxic subpopulation of mature T lymphocytes. Subsets of intestinal intraepithelial lymphocytes express CD8 without CD8. It has been suggested that CD8+- T cells mature extrathymically, while development of the CD8++ population of T cells is thymus-dependent. CD8 acts as a coreceptor with MHC Class I-restricted T cell receptors in antigen recognition and positive selection of MHC class I-restricted CD8+ T cells. In vivo and in vitro treatment with the 53-6.7 monoclonal antibody effectively depletes CD8+ cells.
    Pathways
    TCR Signaling
You are here:
Support